What was the overall market valuation for febrile seizures in South Korea in 2024?

The overall market valuation for febrile seizures in South Korea was $42.0 Million in 2024. Read More

What is the projected market valuation for febrile seizures in South Korea by 2035?

The projected market valuation for febrile seizures in South Korea is $60.0 Million by 2035. Read More

What is the expected CAGR for the South Korea febrile seizures market during the forecast period 2025 - 2035?

The expected CAGR for the South Korea febrile seizures market during the forecast period 2025 - 2035 is 3.3%. Read More

What were the valuations for different types of febrile seizures in 2024?

In 2024, the valuations for febrile seizures types were $15.0 Million for Simple Febrile Seizures, $12.0 Million for Complex Febrile Seizures, and $15.0 Million for Recurrent Febrile Seizures. Read More

How does the treatment type segment perform in the South Korea febrile seizures market?

In 2024, the treatment type segment showed valuations of $20.0 Million for Medication, $12.0 Million for Non-Medication, and $10.0 Million for Emergency Care. Read More

What are the age group valuations for febrile seizures in South Korea?

In 2024, the age group valuations were $10.0 Million for Infants, $8.0 Million for Toddlers, $7.0 Million for Preschool Children, and $17.0 Million for School-Aged Children. Read More

What diagnostic methods are used for febrile seizures in South Korea?

In 2024, diagnostic methods included $10.0 Million for Electroencephalogram, $12.0 Million for Clinical Evaluation, $8.0 Million for Blood Tests, and $12.0 Million for Imaging Tests. Read More

What trends are expected in the South Korea febrile seizures market by 2035?

By 2035, trends in the South Korea febrile seizures market may indicate growth in all segments, with a notable increase in valuations across types, treatment methods, and age groups. Read More

How does the market for febrile seizures in South Korea compare to other regions?

While specific comparisons to other regions are not provided, the South Korea febrile seizures market is poised for growth, driven by key players and increasing awareness. Read More

South Korea Febrile Seizures Market

Q: Which companies are the key players in the South Korea febrile seizures market?

Key players in the South Korea febrile seizures market include Pfizer Inc, Novartis AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., Johnson & Johnson, AstraZeneca PLC, and Eli Lilly and Company. Read More

ID: MRFR/MED/51989-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026

South Korea Febrile Seizures Market Research Report By Type (Simple Febrile Seizures, Complex Febrile Seizures, Recurrent Febrile Seizures), By Treatment Type (Medication, Non-Medication, Emergency Care), By Age Group (Infants, Toddlers, Preschool Children, School-Aged Children) and By Diagnosis Method (Electroencephalogram, Clinical Evaluation, Blood Tests, Imaging Tests) -Forecast to 2035

South Korea Febrile Seizures Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)3.3%

2024 Market Size$ 42 Million

2025 Market Size$ 43.39 Million

2035 Market Size$ 60 Million

Key Players

Pfizer Inc

Novartis AG

GlaxoSmithKline plc

Bristol-Myers Squibb Company

Sanofi S.A.

Johnson & Johnson

Trends

Increased Awareness and Education
Advancements in Treatment Options
Collaboration Between Healthcare Providers and Families

Opportunities

Government Initiatives and Support
Rising Incidence of Febrile Seizures
Growing Parental Concerns and Education

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 Simple Febrile Seizures
  2. 4.1.2 Complex Febrile Seizures
  3. 4.1.3 Recurrent Febrile Seizures
2. 4.2 Life Sciences, BY Treatment Type (USD Million)
  1. 4.2.1 Medication
  2. 4.2.2 Non-Medication
  3. 4.2.3 Emergency Care
3. 4.3 Life Sciences, BY Age Group (USD Million)
  1. 4.3.1 Infants
  2. 4.3.2 Toddlers
  3. 4.3.3 Preschool Children
  4. 4.3.4 School-Aged Children
4. 4.4 Life Sciences, BY Diagnosis Method (USD Million)
  1. 4.4.1 Electroencephalogram
  2. 4.4.2 Clinical Evaluation
  3. 4.4.3 Blood Tests
  4. 4.4.4 Imaging Tests
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis AG (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline plc (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi S.A. (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Johnson & Johnson (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca PLC (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly and Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY AGE GROUP, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY AGE GROUP, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

South Korea South Korea Febrile Seizures Market Segmentation

South Korea Febrile Seizures Market By Type (USD Million, 2025-2035)

Simple Febrile Seizures
Complex Febrile Seizures
Recurrent Febrile Seizures

South Korea Febrile Seizures Market By Treatment Type (USD Million, 2025-2035)

Medication
Non-Medication
Emergency Care

South Korea Febrile Seizures Market By Age Group (USD Million, 2025-2035)

Infants
Toddlers
Preschool Children
School-Aged Children

South Korea Febrile Seizures Market By Diagnosis Method (USD Million, 2025-2035)

Electroencephalogram
Clinical Evaluation
Blood Tests
Imaging Tests

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”